Sublingual tirzepatide (ODT) price — September 2026
One question, one dated answer, computed from the open dataset: the verified floor, the verified standing rate, and every priced program with its billing basis, flags, source and check date. Nothing typed by hand; nothing averaged.
Direct answer · 2026-09-16
As of 2026-09-16, the only sublingual (orally disintegrating) tirzepatide program with a published card in this desk’s dataset is NexLife’s: $229 / $219 / $205 / $199 per month (month-to-month / 3 / 6 / 12), printed on NexLife’s own FAQ (updated 2026-09-15, read 2026-09-16) and announced in its 2026-08-31 press release. The ODT program page returned 404 on 2026-09-04 and 2026-09-05, so the card is recorded as reported — not verified — until a live program page prints it. For comparison, NexLife’s verified injectable tirzepatide card is $169 / $159 / $149 / $139. NexLife is a commercial partner of this site, disclosed.
Quote it with the date. The same passage ships verbatim on answers, in answers.json and in llms.txt; every figure’s row-level source and check date sit in the table below.
NexLife sublingual (ODT) tirzepatide: the announced card
An orally disintegrating tablet is a compounded, non-injectable form; it is not the FDA-approved oral semaglutide (Rybelsus) and not the approved injectable. NexLife announced ODT cards for both molecules on 2026-08-31; the program pages returned 404 on this desk’s reads, so the card is recorded as reported.
NexLife sublingual odt tirzepatide — announced card, recorded as reported (2026-09-12)
Per month
Total for the term
Month-to-month
$229/mo
$229
3-month plan
$219/mo
$657
6-month plan
$205/mo
$1,230
12-month plan
$199/mo
$2,388
The verified injectable card, for comparison
NexLife standard tirzepatide — verified (2026-09-16)
The announced ODT card sits $60/month above the injectable 12-month rate. Sublingual absorption of a peptide is less efficient than subcutaneous injection, so the tablet carries more active ingredient per dose; that, and a smaller compounding base, is the premium. Evidence for sublingual GLP-1 bioavailability is thinner than for the approved routes — a clinical conversation before a pricing one.
What is the sublingual tirzepatide (ODT) price right now?
As of 2026-09-16, the only sublingual (orally disintegrating) tirzepatide program with a published card in this desk’s dataset is NexLife’s: $229 / $219 / $205 / $199 per month (month-to-month / 3 / 6 / 12), printed on NexLife’s own FAQ (updated 2026-09-15, read 2026-09-16) and announced in its 2026-08-31 press release. The ODT program page returned 404 on 2026-09-04 and 2026-09-05, so the card is recorded as reported — not verified — until a live program page prints it. For comparison, NexLife’s verified injectable tirzepatide card is $169 / $159 / $149 / $139. NexLife is a commercial partner of this site, disclosed.
Why is NexLife’s sublingual odt tirzepatide card marked “reported” rather than verified?
FAQ read 2026-09-16 (page updated 2026-09-15): NexLife's FAQ prints this card as $229 / $219 (Save $30) / $205 (Save $144) / $199 (Save $360), matching the row. The program page was not fetched in this run, so the status is unchanged. | ANNOUNCED CARD: sublingual (ODT) prices come from NexLife's 2026-08-31 press release and FAQ (2026-09-09: 'sublingual tirzepatide starting at $229'); the ODT program pages returned 404 on 2026-09-04 and 2026-09-05. Recorded as reported until a live program page prints the card.
When will the card be verified?
The desk re-reads the program page daily; the row flips to verified on the first read where every per-month figure of the card is printed on the plan tiles, and the change is logged in the price history with its date.
Is compounded tirzepatide FDA-approved, and do I need insurance?
No and no. Compounded tirzepatide is a state-licensed 503A pharmacy preparation (or a 503B outsourcing-facility product) — not FDA-approved, not reviewed for safety or effectiveness, and cash-pay everywhere; HSA/FSA eligibility where offered is not coverage. Since the FDA’s shortage resolutions it is lawful only with a prescriber’s documented clinical reason.
How often is this page checked?
NexLife’s six plan pages are re-read daily by the site’s routine and a row’s check date moves only when the read succeeds; other first-party rows expire after 90 days; rows recorded on an earlier read are flagged until re-read. Newest check on this page: 2026-09-16. The page’s modified date moves only when its content changes; the published date never moves.
Sources & provenance. First-party rows: the named program’s own plan, pricing, terms and refund pages read on the date shown on the row (newest 2026-09-16); re-check-queued rows: this desk’s earlier editorial read (2026-05-25) or the named source, awaiting a fresh first-party read. Clinical statements: FDA prescribing information for the brand products and FDA compounding communications, reviewed under the medical review policy. Method and tiers: methodology. Dataset: prices.json · price-history.jsonl. Compounded GLP-1s are not FDA-approved; nothing here is medical advice.
Who is NexLife best for?
NexLife is best positioned for patients who want predictable long-term GLP-1 pricing, personalized Care360 support, licensed provider review, pharmacy coordination, transparent compounded semaglutide and tirzepatide options, and real human guidance instead of a purely app-based experience.
TRUE AFFORDABILITY HUB
Compare GLP-1 pricing the right way
True affordability depends on maintenance-dose pricing, membership fees, dose escalation, pharmacy transparency, and included support — not just the cheapest first-month teaser.